INTRODUCTION
The physiologic effects of insulin are vital for the regulation of carbohydrate and lipid metabolism [248] . In subjects with insulin resistance, elevated glucose production and triglyceride secretion by the liver [33] , an increased release of free fatty acids from adipose tissue [34] , and impaired glucose disposal in peripheral tissues [35] contribute to the pathogenesis of hyperglycemia and dyslipidemia. As such, insulin resistance has a central role in the development of type 2 diabetes and, ultimately, cardiometabolic complications [126] . Thus, strategies to prevent or treat insulin resistance may have a major impact on public health. Although several mechanisms that underlie insulin resistance in the liver, adipose tissue, and muscle have been identified [21] , the cause of insulin resistance in humans remains only partially elucidated.
Parallel to the epidemic rises in obesity, diabetes, and metabolic syndrome, the intake of fructose has increased dramatically in the past decades [249] . The mean fructose consumption in the USA, as estimated from the 1999-2004 NHANES data, is 49 g/day [250] , with even higher numbers reported for children and adolescents [251] , thereby indicating that fructose makes up a substantial portion of the Western diet. There are strong, positive epidemiologic associations between fructose intake and components of the metabolic syndrome [252] and insulin resistance [107] . In addition, fructose-fed rodents [110] , dogs [109] , and monkeys [108] rapidly develop insulin resistance and other metabolic syndrome features, whereas glucose-fed animals do not.
These observations have fueled public and scientific interest in the adverse health effects of fructose with some trials advocating public health policy against fructose consumption [19] . However, results of clinical trials have not been conclusive regarding these effects of fructose. Some diet-intervention trials have suggested that fructose may induce insulin resistance or dyslipidemia (in human subjects as well as in animal models) [111] , whereas other studies have not been able to confirm these adverse metabolic effects of fructose when it is consumed at real-world amounts [112] . A meta-analysis showed that isocaloric fructose consumption improved glycemic control (without affecting fasting plasma insulin concentrations) in patients with diabetes [253] , but -to our knowledge -there have been no previous meta-analyses that have investigated the effect of fructose on glucose homeostasis or insulin sensitivity in nondiabetic subjects. Moreover, the interpretation of the current evidence on the effects of fructose intake is further complicated because intake of high-calorie sweeteners, especially of fructose, is often associated with increased energy intake and weight gain [106] , which have independent effects on metabolic variables. In addition, fructose is commonly consumed together with glucose as sucrose or high-fructose corn syrup, which makes it difficult to dissociate the differential effects of distinct monosaccharides. Consequently, the current major nutrition guidelines lack specific recommendations regarding fructose intake [254, 255] , and there is a need for better evidence-based public advice [112, 254] . 82 In the current study, we performed a systematic review and meta-analysis of controlled diet-intervention trials in nondiabetic subjects to determine whether fructose consumption or overconsumption has adverse effects on insulin sensitivity.
METHODS

Design
The study was designed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [256] . We reported our results according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement [257] . Two investigators (KWH and MRS) independently performed the literature search, study selection, data extraction, and methodologic quality assessment. Disagreement was resolved in consultation with a third investigator (MJS).
Eligibility criteria
We included controlled clinical trials that investigated the effect of fructose intake on markers of insulin sensitivity in normal-weight and overweight or obese nondiabetic adults. Trials were eligible if the diet-intervention duration was ≥5 days. Outcomes of interest included i) indexes of insulin sensitivity derived from fasting blood samples (for instance, fasting plasma insulin concentration [184] and the HOMA-IR [137]), ii) indexes of insulin sensitivity derived from glucose tolerance tests (for instance, Matsuda index [47] and minimal model [46] ), iii) measurements of insulin sensitivity derived from metabolic flux methods (for instance, glucose disposal under hyperinsulinemic-euglycemic clamp conditions [38, 258] ), and iv) measurements of hepatic insulin sensitivity (for instance, insulin-mediated suppression of endogenous glucose production and the hepatic insulin sensitivity index [259] ). If multiple comparisons were eligible from trials that evaluated >2 intervention arms (for instance, low-dose fructose compared with lowdose glucose and high-dose fructose compared with high-dose glucose), we included the dose-matched comparisons between fructose and control carbohydrates, and hypercaloric fructose comparisons if outcomes were also assessed after a well-controlled baseline diet period. We did not include comparisons in which the control diet had a higher caloric content (or higher carbohydrate dose) than the caloric content of the fructose-intervention diet. We also excluded uncontrolled studies, studies in children or adolescents, studies that used parenteral fructose administration, and studies with follow-up <5 days. Because the metabolic effects of fructose in patients with diabetes have been reviewed [253, 260] , we did not include studies in patients with diabetes. We applied no restrictions on other comorbid conditions.
Information sources and search
We searched, independently and in duplicate, for relevant publications in the MED-LINE (http://www.ncbi.nlm.nih.gov/pubmed), EMBASE (http://ovidsp.tx.ovid.com), and Cochrane Library (http://www.cochranelibrary.com) databases from inception through 14 September 2016. The full search strategy is presented in Supplemental Table S1 and included search terms for fructose and insulin sensitivity or markers of insulin resistance in combination with an ultrasensitive search strategy for controlled trials (sensitivity 98.9-99.5%) [261, 262] . We manually reviewed reference lists of selected articles for additional publications. There were no language restrictions.
Study selection
All entries that were identified through the literature search were screened for relevant articles on the basis of predetermined eligibility criteria. Full-text publications were retrieved for entries that were accepted by ≥1 investigator and were evaluated independently by 2 investigators for eligibility.
Data extraction
Predefined data were extracted from each report with the use of standardized forms. We extracted information on study characteristics, study-participant characteristics, baseline diet, intervention and control diets, outcomes of interest, and information used to assess the methodologic quality of studies. Primary outcomes were MDs ± standard errors (SEs) in markers of insulin sensitivity between fructose-intervention diets and control diets. We used a conversion factor of 1 mU/l = 6 pmol/l to convert insulin concentrations to Système International units [263] . When primary outcome data were not reported numerically, we extracted data from figures with the use of Plot Digitizer v2.6.8 (Joseph A. Huwaldt, http://plotdigitizer.sourceforge.net/). Additional information was requested from the authors of most articles.
When articles did not report the SE of the MD, it was calculated from available statistics [for instance, standard deviation (SD), p value, or t statistic] with the use of standard formulas [256] . When these statistics were not reported, missing SDs were imputed with the use of a pooled SD that was derived from the other trials (Supplemental Table S2 ) [256] .
Effect sizes and variances for crossover trials were calculated in accordance with the Cochrane Handbook [256] . Briefly, when the mean ± SE of within-participant differences was not reported and could not be retrieved from the authors, we calculated the effect size as the difference between mean outcomes after fructose and control periods and i) retrieved the SE of the MD between the paired observations from reported paired p values or t statistics [264] or ii) imputed the SE of the MD with the use of the reported variance after each period with the assumption of a conservative correlation coefficient of 0.5 to approximate the paired analyses.
Risk of bias in individual studies
We assessed the methodologic quality of individual studies with the use of the Heyland methodological quality score (MQS) [265] . Studies with an MQS ≥8 were considered to be of high quality.
Synthesis of results
In line with other analyses of carbohydrate consumption [266] [267] [268] [269] [270] [271] [272] , energy-matched and hypercaloric comparisons were analyzed separately. In energy-matched comparisons, fructose substituted control carbohydrates isocalorically (that is, the fructose-intervention diet and control diet had the same energy contents). In hypercaloric comparisons, 84 surplus energy from fructose was added to a weight-maintenance control diet (that is, the fructose-intervention diet had a higher energy content than that of the control diet). When >2 studies reported quantitative data on the same outcome variable, results were pooled with the use of the generic inverse-variance method with random-effects models. Pooled data are expressed as MDs (95% CIs) for fasting plasma insulin concentrations and HOMA-IR and as SMDs (95% CIs) (that is, the MD divided by the pooled SD [256] ) for insulin-stimulated glucose disposal and hepatic insulin sensitivity.
We assessed intertrial heterogeneity with the use of Cochran's Q statistic (p<0.10 was considered significant) and quantified heterogeneity with the I 2 statistic (I 2 >50% indicated moderate heterogeneity, and I 2 >75% indicated high heterogeneity). Sources of heterogeneity were evaluated by the removal of individual trials in sensitivity analyses and through a priori subgroup analyses.
Data were analyzed with the use of Review Manager v5.3 [273] and IBM SPSS Statistics v23 (Armonk, NY, USA). Reported p values are 2-tailed, and p<0.05 was considered significant.
Risk of bias across studies
Publication bias was assessed by an inspection of funnel plots and the use of Egger's tests [274] .
Additional analyses
We performed sensitivity analyses to determine whether the overall results were affected by i) the inclusion of studies with low methodologic quality (MQS <8) in the meta-analysis, ii) the use of more-(0.25) or less-(0.75) conservative correlation coefficients to approximate paired analyses in crossover studies, iii) the imputation of missing SDs with the use of a pooled SD from the other trials, and iv) the inclusion of studies with >2 arms (for instance, low-dose fructose compared with low-dose glucose and high-dose fructose compared with high-dose glucose in a paired design). In addition, we repeated all meta-analyses with the use of fixed-effects models, which gave proportionally more weight to larger, more precise trials [275] .
RESULTS
Study selection
A flow diagram of the study selection process is shown in Figure 6 .1. We identified 1240 original records through electronic and manual searches. Twenty-nine articles met the eligibility criteria [116, 118, .
Study characteristics
Study characteristics of included diet-intervention studies are shown in Table 6 .1. The 29 included articles provided data for the following 46 comparisons: 32 energy-matched comparisons in which fructose substituted control carbohydrates isocalori-cally and 14 hypercaloric comparisons in which surplus energy from fructose was added to a weight-maintenance control diet.
The study by Madero et al [291] was performed in Mexico. The other studies were conducted in Western Europe or the USA. Eighteen trials (56%) that were energy matched and 12 trials (86%) that were hypercaloric studies used crossover designs. Seventeen energy-matched comparisons (53%) and 7 hypercaloric comparisons (50%) were randomized. Studies tended to have been of short durations and with small sample sizes; median [interquartile range (IQR)] durations of follow-up were 28 (14-37) days and 7 (7-15) days in energy-matched and hypercaloric studies, respectively, whereas median (IQR) sample sizes were 18 (10-32) and 12 (10-16) in energy-matched and hypercaloric studies, respectively. Fructose was provided as beverages, crystalline fructose, or natural solid foods. The mean fructose dose in each study ranged from 26-293 g/day. Doses tended to be higher in the hypercaloric comparisons ( Table 6 .1). Fructose was compared with glucose, sucrose, starch, galactose, dextromaltose, or a mixture of nutrients in energy-matched comparisons. All hypercaloric studies compared a diet that was supplemented with fructose to the same diet without fructose supplementation. In these comparisons, the mean dietary caloric surplus from fructose ranged from 18-33% of total energy intake.
The median (IQR) Heyland MQS was 7 (6-8) in both energy-matched and hypercaloric comparisons (Supplemental Table S3 ). Eleven energy-matched comparisons (34%) and 6 hypercaloric comparisons (43%) had MQSs ≥8, which were indicative of high quality.
Effect of fructose on fasting plasma insulin concentrations
The energy-matched substitution of dietary carbohydrates with fructose had no effect on fasting insulin concentrations in the overall analysis (MD: −0.79 pmol/l, 95% CI: −6.41-4.84 pmol/l, p=0.78; Figure 6 .2A). Isocaloric fructose intake tended to raise fasting insulin concentrations in overweight or obese subjects (MD: 7.10 pmol/l, 95% CI: −0.07-14.27 pmol/l, p=0.05). There was significant intertrial heterogeneity in both the normal-weight subgroup and the subgroup with other metabolic features (I 2 =67%, p<0.01 and I 2 =83%, p<0.01, respectively) as well as in the overall pooled analysis (I 2 =69%, p<0.01).
In hypercaloric comparisons, fructose supplementation slightly raised fasting insulin concentrations by 3.38 pmol/l (95% CI: 0.03-6.73 pmol/l; p<0.05) in the overall analysis (Figure 6.2B) . The effect was most outspoken in OffT2D subjects in the study by Lê et al [301] (MD: 11.29 pmol/l, 95% CI: 5.36-17.21 pmol/l, p<0.01). Hypercaloric fructose diets did not induce any insulin-raising effects in normal-weight or overweight and obese subgroups.
Finally, although we were unable to retrieve quantitative data for pooling, Huttunen et al [282] reported no differences in fasting insulin concentrations between normal-weight participants who used either fructose (n=35) or sucrose (n=33) as a dietary sweetener for 95 weeks, and Mark et al [292] reported no differences in fasting insulin concentrations between overweight or obese participants who consumed diets with low or high advanced glycation end products that were supplemented with either fructose (n=35) or glucose (n=38) for 28 days. 
Effect of fructose on insulin-stimulated glucose disposal rates
Insulin-stimulated glucose disposal, which is assessed under hyperinsulinemic-euglycemic clamp conditions, is the best variable of whole-body insulin sensitivity in vivo [38] . Fructose intake had no effect on insulin-stimulated glucose disposal in primary pooled analyses of energy-matched comparisons (SMD: 0.00, 95% CI: −0.41-0.41, p=1.00; Figure 6 .4A) or of hypercaloric comparisons (SMD: 0.10, 95% CI: −0.21-0.40, p=0.54; Figure 6 .4B). There was no evidence of intertrial heterogeneity or subgroup differences.
Effect of fructose on hepatic insulin sensitivity
Hepatic insulin sensitivity was assessed with the use of the insulin-mediated suppression of endogenous glucose production under hyperinsulinemic-euglycemic clamp conditions [277, 286, [299] [300] [301] , which was the preferred method for pooling, or with the use of the hepatic insulin sensitivity index [284] . In normal-weight, nondiabetic participants, the isocaloric substitution of control carbohydrates with fructose induced hepatic insulin resistance (SMD: 0.47, 95% CI: 0.03-0.91, p=0.04; Figure 6 .5A) without evidence of intertrial heterogeneity (I 2 =17%, p=0.30). In accordance, hypercaloric fructose supplementation reduced hepatic insulin sensitivity in normal-weight nondiabetic subjects and in OffT2D subjects (SMD: 0.77, 95% CI: 0.28-1.26, p<0.01; Figure 6 .5B). There was moderate intertrial heterogeneity within the normal-weight subgroup (I 2 =64%, p=0.04).
Effect of fructose on other markers of insulin sensitivity
We identified several other outcomes of insulin sensitivity. In energy-matched comparisons between fructose-and glucose-intervention arms, there were no differences in i) the updated homeostasis model assessment of insulin resistance [276] , ii) the Matsuda index of insulin sensitivity derived from an oral-glucose-tolerance test (OGTT) [287] , iii) another OGTT-based insulin sensitivity index [292] , iv) the rate of glucose disappearance during an intravenous insulin tolerance test [279] , and v) an insulin-sensitivity index derived from the deuterated-glucose disposal test [294] . In the study by Koh et al [283] , normal-weight subjects (n=9) and subjects with IGT (n=9) had lower glucose and insulin excursions during an OGTT after the 4-week high-fructose diet than after the 4-week high-glucose diet.
In hypercaloric comparisons, fructose that provided surplus energy had no effect on the rate of glucose disappearance during an intravenous insulin tolerance test [279] , but it did reduce the Matsuda index of insulin sensitivity [287] and induced lower insulin sensitivity during the deuterated-glucose disposal test [294] . Because these outcomes were not reported in >2 studies, we did not pool the results.
Publication bias
A visual inspection of funnel plots suggested that there was mild asymmetry in energy-matched comparisons for the HOMA-IR (Egger's test: p=0.10; Supplemental Figure  S1 ). There was no evidence of funnel plot asymmetry for fasting insulin meta-analyses (Egger's test: p>0.68; Supplemental Figures S2 and S3 ) or in hypercaloric comparisons for HOMA-IR (Egger's test: p=0.32; Supplemental Figure S4 ). We could not meaningfully evaluate publication bias for glucose disposal and hepatic insulin resistance outcomes because of the small number of studies. Additional analyses and sources of heterogeneity Sensitivity analyses showed that the results were consistent when we limited the analyses to high-quality studies, excluded trials that had SDs imputed, used more-or less-conservative correlation coefficients to approximate paired analyses in crossover studies, excluded trials with >2 intervention arms, or used fixed-effects models instead of random-effects models (Supplemental Tables S4 to S6 ). Overall, there was little intertrial heterogeneity throughout the analyses. The systematic removal of individual comparisons revealed that most heterogeneity was caused by a few studies, in particular the 2 comparisons from the study by Koh et al [283] and the comparison in OffT2D subjects from the study by Lê et al [301] . The comparisons by Koh et al [283] were small and may have had heterogeneous results by chance. Also, Koh et al [283] did not report SDs for their outcomes, and we imputed a pooled SD that was derived from the other trials (Supplemental Table S2 ), which may have been inappropriately precise for this study. However, the removal of these comparisons did not alter the effects. Another source of heterogeneity was that Lê et al [301] selectively studied OffT2D subjects, who may have had distinct metabolic characteristics.
DISCUSSION
Summary of evidence
Data from the current systematic review and meta-analysis of 46 comparisons in 1005 participants showed that both isocaloric fructose consumption and hypercaloric fructose consumption induce hepatic insulin resistance in normal-weight, nondiabetic adults. Short-and medium-term fructose consumption does not promote muscle or peripheral insulin resistance as was shown by the lack of a change in insulin-stimulated glucose disposal in all analyses. In addition, the energy-matched (isocaloric) substitution of dietary carbohydrates for fructose had no effect on fasting insulin concentrations and the HOMA-IR, whereas hypercaloric fructose supplementation raised fasting insulin concentrations and the HOMA-IR in OffT2D subjects but not in normal-weight and overweight or obese participants. These results were remarkably robust in all sensitivity analyses. There also was little heterogeneity throughout the analyses except for heterogeneity caused by a few select studies.
One finding was of particular interest, whereby both the isocaloric exchange of control carbohydrates (mostly glucose) by fructose and hypercaloric fructose supplementation induced hepatic insulin resistance. This result indicated that the promotion of hepatic insulin resistance by fructose could not be attributed only to excess energy intake (and associated weight gain [266] ) under hypercaloric diet conditions. Instead, fructose has an ability to induce metabolic changes in the liver that is inherently different from the effect of glucose and other carbohydrates. Fructose is preferentially metabolized by the liver on the first pass and bypasses the major regulatory steps in glycolysis, thereby leading to a rapid buildup of downstream intermediaries [303, 304] . Elevated intrahepatic fructose intermediaries may alter hepatic gene-expression patterns, promote glucose production, and act as uncontrolled substrates for de novo lipogenesis [111, 305] associated with the development of hepatic insulin resistance [306] . Moreover, high-fructose diets have consistently caused insulin resistance in animal models [108] [109] [110] . Therefore, the hepatic insulin resistance-inducing effect of fructose is mechanistically plausible and consistent with evidence from animal and epidemiologic studies. The near-complete first-pass extraction of fructose from portal blood may also explain why no study to date -to our knowledge -has shown that short-term fructose consumption promotes muscle insulin resistance. . Across these previous aggregate analyses, there was no effect of isocaloric 98 fructose intake, but there were adverse effects of hypercaloric fructose intake. These results suggest that some of the adverse metabolic effects of fructose under hypercaloric conditions may be attributed in part to increased energy intake rather than to fructose itself. For the first time -to our knowledge -we provide aggregate evidence to support suspicions that fructose consumption is worse than the (isocaloric) consumption of other carbohydrates with respect to hepatic insulin resistance.
Thus, current evidence clearly implicates the consumption of excess energy from fructose in the development of several features of metabolic disease. Most adults (especially the overweight or obese) should avoid being in a positive energy balance. Already, this advice has been recommended in nutrition guidelines [254, 255] and has been the focus of many public health policies. The current study more specifically implicates fructose to be more harmful than other carbohydrates, even over the short-to-medium term, with regard to hepatic insulin sensitivity. This outcome indicates that the type of carbohydrate matters and is relevant at a time when public interest in and media attention for the adverse health effects of fructose are high. Hepatic insulin resistance is associated with early stages of diabetes development [176] and is considered 1 of the main contributors to hyperglycemia in type 2 diabetes [200] , thereby suggesting the intriguing hypothesis that the amelioration of hepatic insulin resistance by a reduction of fructose intake may have a positive impact on the incidence of type 2 diabetes and public health. Although some foods that are high in free fructose, including whole fruit, can be included in healthy diets [255] , most fructose is currently consumed as added sugar (together with glucose in sucrose or high-fructose corn syrup). Therefore, a simple way to reduce fructose intake is to limit added sugars [255] . However, practically, it may be easier to regulate certain types of sugar than to reduce sugar intake altogether. Low-fructose sweeteners include free glucose, maltose, or rice-malt syrup, and these substitutes may be healthier with regard to hepatic insulin resistance although this possibility should first be confirmed in longer and larger future studies.
In contrast, in patients with diabetes, isocaloric fructose consumption improved glycemic control, possibly because of the low glycemic index of fructose [253] , but also conditionally raised triglyceride concentrations [260] . Although beyond the scope of this review, previous studies have assessed the effect of fructose on markers of insulin sensitivity in subjects with diabetes [297, [307] [308] [309] [310] [311] . One study in 6 subjects with type 2 diabetes showed that hepatic insulin sensitivity was not affected by isocaloric fructose consumption [307] . Consequently, our findings may not hold for patients with diabetes, and a systematic review of the diabetes literature on this issue could be the focus of future work. Eventually, recommendations regarding fructose intake may have to differentiate between nondiabetic adults and diabetes patients.
Limitations and future research needs
Several factors may have limited the strength or generalizability of our conclusions. We restricted the analysis to studies in nondiabetic adults, and this restriction may have limited the number of studies that were available for inclusion. The available trials tended to be small, short, and of low quality. We identified only 3 trials in a total of 28 normal-weight men that evaluated the effect of isocaloric fructose on hepatic insulin sensitivity. Although there was no heterogeneity across the trials, the implication of the results for the general population, including adults of both sexes, and for all ages and ethnicities is uncertain. The exclusion of studies in children or adolescents and patients with diabetes, in particular, may have affected the generalizability of our conclusions. Therefore, our conclusions are limited to nondiabetic adults. In addition, many people are exposed to fructose in their (long-term) regular diets. In longer and larger studies, subtle effects of fructose on peripheral insulin sensitivity may become apparent. Unexplained heterogeneity (inconsistency that could not be explained by sensitivity and subgroup analyses) and imprecision in the effect estimates also contributed to uncertainty in the findings. Finally, most studies provided pure (free) fructose in higher doses than real-world human exposure; in 25 energy-matched studies (78%) and 13 hypercaloric studies (93%), the mean daily fructose dose was (much) higher than the mean USA intake of 49 g/day [250] . Our results were consistent across the vastly different fructose doses, but it will be of interest to determine whether there is a dose threshold for harm and to learn more about the adverse health effects of unbound fructose compared with those of other fructose-containing sugars such as sucrose or high-fructose corn syrup. Therefore, there is a need for high-quality studies at lower fructose doses over longer periods of time in both men and women to determine whether real-world fructose exposure has adverse effects on insulin sensitivity and other metabolic variables and to determine recommended maximum intake.
Conclusions
Fructose consumption in an energy-matched exchange for other carbohydrates or in hypercaloric supplementation to a weight-maintenance control diet in short-term controlled diet-intervention trials promotes the development of hepatic insulin resistance in nondiabetic adults. The data do not support meaningful effects of short-term isocaloric or hypercaloric fructose on fasting insulin concentrations, HOMA-IR, or peripheral or muscle insulin sensitivity. However, fructose raised fasting insulin and HOMA-IR in OffT2D subjects consuming a hypercaloric high-fructose diet. These conclusions are limited by the small sample sizes and short durations (mostly <60 days) of included trials but clearly illustrate the need for large, long-term randomized controlled studies to evaluate whether real-world fructose consumption has adverse effects on insulin sensitivity and long-term outcomes.
